ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2813

Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis

Cecilia Svanberg 1, Helena Enocsson 1, Klara Martinsson 1, Lawrence Potempa 2, Ibraheem Rajab 2, Jonas Wetterö 1, Marie Larsson 1 and Christopher Sjöwall3, 1Linköping University, Linköping, Sweden, 2Roosevelt University, Chicago, IL, 3Department of Clinical and Experimental Medicine, Rheumatology/Division of Neuro and Inflammation Sciences, Linköping University, Linköping, Sweden

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Acute-phase reactants, C-reactive protein (CRP) and autoantibodies, interferons, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T115: SLE – Etiology & Pathogenesis I: Signaling Pathways (2810–2815)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune systemic disease affecting multiple organs and which is characterized by autoantibodies directed against nuclear constituents. Common autoantibody targets include double-stranded (ds) DNA and small nuclear ribonucleoproteins (snRNPs; i.e. U1-snRNP). Uptake of immune complexes (ICs) by plasmacytoid dendritic cells (pDCs) can activate endosomal toll-like receptors (TLRs) such as TLR-7 and TLR-9 if nucleic acids are present in the ICs. Such activation is dependent on IC internalization by Fcγ receptor type IIa (FcγRIIa), and results in production of type I interferons (IFNs), a hallmark of SLE and a target for therapeutic interventions. The acute phase protein C-reactive protein (CRP) binds FcγRs, as well as some nuclear proteins, including snRNPs. Pentameric (native) CRP has previously been suggested to inhibit the production of type I IFNs in peripheral mononuclear cells (PBMCs) in response to ICs formed by autoantibodies against snRNP, an effect which was further investigated herein.

Methods: PBMCs or magnetically (MACS) purified pDCs were retrieved from whole blood of healthy volunteers. Type I IFN gene transcription and production was stimulated by addition of snRNP containing ICs +/- pentameric CRP (pCRP) or monomeric CRP (mCRP) in different sequential order. IC formation was achieved through simultaneous addition of snRNP and bulk IgG, retrieved from an SLE patient with high levels of snRNP autoantibodies, directly to the cells. Type I IFNs and inflammatory cytokines were investigated using quantitative PCR, ELISA and cytometric bead array, and cells responsible for production of the type I IFNs were characterized using flow cytometry. For statistics, a two-tailed t-test was performed.

Results: pCRP had an inhibitory effect on the IFN gene expression in PBMCs after incubation with ICs, p=0.044 for IFNα4 and p=0.047 for IFNβ at the 4h time-point compared to IC only. pCRP also showed a dose-dependent inhibitory effect on the type I IFN production in the cells. The monomeric form of CRP showed modest or no effect on IFN levels; p=0.82 for IFNα4 and p=0.58 for IFNβ at the 4h time-point, compared to IC only. A pre-incubation of the cells with pCRP increased the inhibitory effects compared to simultaneous addition of pCRP and ICs, suggesting that initial binding to the cells is a critical step for inhibition. Flow cytometry suggested that pDCs are the main producer of the type I IFNs. In addition, pCRP seems to have a more general inhibitory effect on type I IFNs, as seen in the reduction of IFN production in response to the TLR-9 ligand CpG.

Conclusion: pCRP has a distinct inhibitory effect on type I IFNs, which is largely not seen for the dissociated form of CRP (mCRP). The more general inhibitory effects shown by pCRP highlights its immune regulatory function in pathologies characterized by high production of type I IFNs. The identity of the initial receptors responsible for pCRP mediated effects, as well as of the involved signaling pathways, will be further investigated.


Disclosure: C. Svanberg, None; H. Enocsson, None; K. Martinsson, None; L. Potempa, None; I. Rajab, None; J. Wetterö, None; M. Larsson, None; C. Sjöwall, None.

To cite this abstract in AMA style:

Svanberg C, Enocsson H, Martinsson K, Potempa L, Rajab I, Wetterö J, Larsson M, Sjöwall C. Pentameric, but Not Monomeric C-reactive Protein, Limits the SnRNP-immune Complex Triggered Type I Interferon Response: Implications for Lupus Pathogenesis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/pentameric-but-not-monomeric-c-reactive-protein-limits-the-snrnp-immune-complex-triggered-type-i-interferon-response-implications-for-lupus-pathogenesis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pentameric-but-not-monomeric-c-reactive-protein-limits-the-snrnp-immune-complex-triggered-type-i-interferon-response-implications-for-lupus-pathogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology